Practical issues and challenges in idiopathic pulmonary fibrosis

Respiration

Volumn 86, Issue 1, 2013, Pages 1-4

  Cottin, Vincent ^a   Camus, Philippe ^b  

^a UNIVERSITÉ LYON 1   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; ANTIOXIDANT; BMS 986202; FG 3019; IW001; MONOCLONAL ANTIBODY; NINTEDANIB; OXIDOREDUCTASE INHIBITOR; PRM 151; PROTEIN INHIBITOR; RESPIRATORY TRACT AGENT; SIMTUZUMAB; STX 100; UNCLASSIFIED DRUG; XAQ 576;

AIR POLLUTION; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPLICATION; CONNECTIVE TISSUE DISEASE; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED PRACTICE; EXERCISE; FIBROSING ALVEOLITIS; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; KNOWLEDGE; LUNG EMPHYSEMA; LUNG FIBROSIS; MORTALITY; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; STANDARDIZATION; CANADA; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CRYOBIOPSY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOSCOPIC BIOPSY; EUROPE; FAMILIAL DISEASE; IMMUNE DYSREGULATION; JAPAN; MOLECULAR PATHOLOGY; PHARMACEUTICAL CARE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS INFECTION;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; REVIEW LITERATURE AS TOPIC;

EID: 84879481746     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000353571     Document Type: Review

References (52)

1. Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P: Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: A 3-year prospective study. Eur Respir J 2012; 40: 101-109
2. Spagnolo P, du Bois R, Cottin V: Rare lung disease and orphan drug development. Lancet Respir Med 2013, in press
3. Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972
4. Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB: The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66: 462-467
5. Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ: Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985
6. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D: Incidence and prevalence of idiopathic pulmonary fibrosis: Review of the literature. Eur Respir Rev 2012; 21: 355-361
7. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664
8. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ: An Official ATS/ ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824
9. Wells AU: Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev 2013; 22: 158-162
10. Behr J: Evidence-based treatment strategies in idiopathic pulmonary fibrosis. Eur Respir Rev 2013; 22: 163-168
11. du Bois RM: An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 141-146
12. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE Jr, Wolters PJ, Collard HR: Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013, E-pub ahead of print
13. Poletti V, Ravaglia C, Buccioli M, Tantalocco P, Piciucchi S, Dubini A, Carloni A, Chilosi M, Tomassetti S: Idiopathic pulmonary fibrosis: Diagnosis and prognostic evalution. Respiration 2013; 86: 5-12
14. Judge EP, Fabre A, Adamali HI, Egan JJ: Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012; 40: 93-100
15. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Muller- Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ: Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643
16. Antoniou KM, Cottin V: The challenge of acute exacerbation of pulmonary fibrosis. Respiration 2012; 83: 13-16
17. Simon-Blancal V, Freynet O, Nunes H, Bouvry D, Naggara N, Brillet PY, Denis D, Cohen Y, Vincent F, Valeyre D, Naccache JM: Acute exacerbation of idiopathic pulmonary fibrosis: Outcome and prognostic factors. Respiration 2012; 83: 28-35
18. Song JW, Hong SB, Lim CM, Koh Y, Kim DS: Acute exacerbation of idiopathic pulmonary fibrosis: Incidence, risk factors and outcome. Eur Respir J 2011; 37: 356-363
19. Pitsiou G, Papakosta D, Bouros D: Pulmonary hypertension in idiopathic pulmonary fibrosis: A review. Respiration 2011; 82: 294-304
20. Günther A, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P: Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 152-160
21. Richeldi L, Collard HR, du Bois RM, Jenkins G, Kolb M, Maher TM, Raghu G, Vancheri C, Laurent GJ: Mapping the future for pulmonary fibrosis. Eur Respir J 2013, E-pub ahead of print
22. Wuyts WA, Agostini C, Antoniou K, Bouros D, Chambers R, Cottin V, Egan J, Lambrecht B, Lories R, Parfrey H, Prasse A, Robalo-Cordeiro C, Verbeken E, Verschakelen J, Wells A, Verleden G: The pathogenesis of pulmonary fibrosis: A moving target. Eur Respir J 2013; 41: 1207-1218
23. Tzouvelekis A, Ntolios P, Bouros D: Stem cell treatment for chronic lung diseases. Respiration 2013; 85: 179-192
24. Cottin V: Significance of connective tissue disease features in pulmonary fibrosis. Eur Respir Rev 2013, in press
25. Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, Aso H, Sakamoto K, Hasegawa Y: Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 2013; 85: 456-463
26. Savale L, Bertoletti L, Cottin V: Should we screen for pulmonary hypertension at the initial evaluation of idiopathic pulmonary fibrosis? Respiration 2013; 85: 452-455
27. Nathan SD, Cottin V: Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Eur Respir Mon 2012; 57: 148-160
28. Hoeper MM, Halank M, Wilkens H, Günther A, Weimann G, Gebert I, Leuchte HH, Behr J: Riociguat for interstitial lung disease and pulmonary hypertension: A pilot trial. Eur Respir J 2013; 41: 853-860
29. Cottin V: Treatment of pulmonary hypertension in interstitial lung disease: Do not throw out the baby with the bath water. Eur Respir J 2013; 41: 781-783
30. Richeldi L: Idiopathic pulmonary fibrosis: Current challenges and future perspectives. Eur Respir Rev 2013; 22: 103-105
31. Cottin V: Interstitial lung disease. Eur Respir Rev 2013; 22: 26-32
32. Cottin V: Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir Rev 2012; 21: 161-167
33. Richeldi L: Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 147-151
34. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829
35. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377: 1760-1769
36. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087
37. Vancheri C, du Bois RM: A progression-free end-point for idiopathic pulmonary fibrosis trials: Lessons from cancer. Eur Respir J 2013; 41: 262-269
38. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L: Hot of the breath: Mortality as a primary end-point in IPF treatment trials: The best is the enemy of the good. Thorax 2012; 67: 938-940
39. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK: Idiopathic pulmonary fibrosis: Clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044-1048
40. du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW: Idiopathic pulmonary fibrosis: Lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012; 186: 712-715
41. Huppmann P, Sczepanski B, Boensch M, Winterkamp S, Schonheit-Kenn U, Neurohr C, Behr J, Kenn K: Effects of in-patient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 2012, E-pub ahead of print
42. Maher TM: PROFILEing idiopathic pulmonary fibrosis: Rethinking biomarker discovery. Eur Respir Rev 2013; 22: 148-152
43. Zhang Y, Kaminski N: Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012; 18: 441-446
44. Cottin V: The impact of emphysema in pulmonary fibrosis. Eur Respir Rev 2013; 22: 153- 157
45. Savarino E, Carbone R, Marabotto E, Furnari M, Sconfienza L, Ghio M, Zentilin P, Savarino V: Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J 2013, E-pub ahead of print. 46 Raghu G, Meyer KC: Silent gastro-oesophageal reflux and microaspiration in IPF: Mounting evidence for anti-reflux therapy? Eur Respir J 2012; 39: 242-245
46. Königshoff M: Lung cancer in pulmonary fibrosis: Tales of epithelial cell plasticity. Respiration 2011; 81: 353-358
47. Gribbin J, Hubbard R, Smith C: Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 2009; 103: 927-931
48. Spagnolo P, Luppi F, Cerri S, Richeldi L: Genetic testing in diffuse parenchymal lung disease. Orphanet J Rare Dis 2012; 7: 79
49. Devine MS, Garcia CK: Genetic interstitial lung disease. Clin Chest Med 2012; 33: 95-110
50. Frank RC, Hicks S, Duck AM, Spencer L, Leonard CT, Barnett E: Ambulatory oxygen in idiopathic pulmonary fibrosis: Of what benefit? Eur Respir J 2012; 40: 269-270
51. Lee JS, McLaughlin S, Collard HR: Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2011; 17: 348-354
52. Cordier JF, Cottin V: Neglected evidence in idiopathic pulmonary fibrosis: From history to earlier diagnosis. Eur Respir J 2013, E-pub ahead of print